Invention Application
WO2011143484A1 A SUSTAINED RELEASE FORMULATION OF METHOTREXATE AS A DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARD) AND AN ANTI-CANCER AGENT
审中-公开
甲状腺激素释放调节剂作为抗病毒药物（DMARD）和抗癌药物的持续释放
- Patent Title: A SUSTAINED RELEASE FORMULATION OF METHOTREXATE AS A DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARD) AND AN ANTI-CANCER AGENT
- Patent Title (中): 甲状腺激素释放调节剂作为抗病毒药物（DMARD）和抗癌药物的持续释放
-
Application No.: PCT/US2011/036328Application Date: 2011-05-12
-
Publication No.: WO2011143484A1Publication Date: 2011-11-17
- Inventor: GARCIA, Louie, Daniel , GIBSON, Lois , LAMBERT, William , LI, Benjamin , ZHU, Liangjin
- Applicant: PACIRA PHARMACEUTICALS, INC. , GARCIA, Louie, Daniel , GIBSON, Lois , LAMBERT, William , LI, Benjamin , ZHU, Liangjin
- Applicant Address: 10450 Science Center Drive San Diego, CA 92121 US
- Assignee: PACIRA PHARMACEUTICALS, INC.,GARCIA, Louie, Daniel,GIBSON, Lois,LAMBERT, William,LI, Benjamin,ZHU, Liangjin
- Current Assignee: PACIRA PHARMACEUTICALS, INC.,GARCIA, Louie, Daniel,GIBSON, Lois,LAMBERT, William,LI, Benjamin,ZHU, Liangjin
- Current Assignee Address: 10450 Science Center Drive San Diego, CA 92121 US
- Agency: HART, Daniel
- Priority: US61/334,546 20100513; US12/914,944 20101028
- Main IPC: A61K9/127
- IPC: A61K9/127 ; A61P35/00 ; A61K31/519 ; A61P37/00
Abstract:
Disclosed is are formulations comprising a multivesicular liposome and MTX, the administration of which results in a C max of MTX between 5% and 50% of the C max of an immediate release dosage form of MTX, the duration of which lasts from about 1 to about 30 days. Also disclosed are methods of treating autoimmune diseases and cancer by administering these formulations of MTX.
Information query
